343
Participants
Start Date
July 31, 2016
Primary Completion Date
June 30, 2023
Study Completion Date
June 30, 2023
Eflornithine
Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 week on, 1 week off schedule
Lomustine
Lomustine 90 mg/m2 administered orally once every 6 weeks
Lomustine
Lomustine 110 mg/m2 administered orally once every 6 weeks
Universitair Ziekenhuis Leuven, Leuven
Cliniques Universitaires UCL De Mont-Godinne, Yvoir
Mount Sinai Hospital, New York
Columbia University Medical Center, The Neurological Institute, New York
Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino - Ospedale Molinette, Torino
Hôpital de la Timone, Marseille
University of Pennsylvania, Philadelphia
Thomas Jefferson University Hospital, Philadelphia
Fondazione IRCCS - Instituto Neurologico Carlo Besta, Milan
Universitaetsklinikum Hamburg-Eppendorf, Hamburg
Centre Georges François Leclerc, Dijon
Wake Forest University Health Sciences, Winston-Salem
University of North Carolina - Chapel Hill, Chapel Hill
Duke University Medical Center, Durham
CHRU de Brest, Brest
Medical University of South Carolina, Hollings Cancer Center, Charleston
Piedmont Physicians Neuro-Oncology, Atlanta
Winship Cancer Institute, Atlanta
University of South Florida (USF) - H. Lee Moffitt Cancer Center and Research Institute, Tampa
University of Alabama at Birmingham, Birmingham
Vanderbilt University, Nashville
Norton Cancer Institute - Louisville, Louisville
Heinrich-Heine-Universitat Duesseldorf, Düsseldorf
University of Kentucky Chandler Medical Center, Lexington
OhioHealth Research and Innovation Institute, Columbus
The Cleveland Clinic, Richard E. Jacobs Health Center, Cleveland
Universitätsklinikum Essen, Essen
Henry Ford Hospital, Detroit
Institut de Cancerologie de l'Ouest - Angers, Angers
The University of Iowa, Iowa City
Mayo Clinic Minnesota, Rochester
Hôpital Roger Salengro, Lille
Northwestern Medicine CDH Cancer Center, Warrenville
Northwestern University, Chicago
Centre Jean Perrin, Clermont-Ferrand
Washington University, St Louis
Saint Luke's Cancer Institute, Kansas City
HCA Midwest Division, Kansas City
Hôpital Pierre Wertheimer - Hospices Civils de Lyon, Bron
Louisiana State University Health Sciences Center New Orleans, New Orleans
Hôpital Universitaire Pitié Salpêtrière, Paris
Neuro-Oncology Associates, Dallas
MD Anderson Cancer Center, Houston
Texas Oncology Austin Brain Tumor Center, Austin
University of Colorado, Aurora
University of Utah, Salt Lake City
Saint Joseph's Hospital and Medical Center, Phoenix
Kaiser Permanente, Los Angeles
University of Southern California Norris Comprehensive Cancer Center, Los Angeles
John Wayne Cancer Institute, Santa Monica
UCSD Moores Cancer Center, San Diego
University of California Irvine Medical Center, Orange
Klinik und Poliklinik fur Neurologie der Universitat Regensburg, Regensburg
Kaiser Permanente Center, Redwood City
University of California San Francisco Medical Center, San Francisco
Kaiser Permanente, Sacramento
Providence Brain & Spine Institute, Portland
Swedish Health Services, Seattle
Maine Center for Cancer Medicine and Blood Disorders, Scarborough
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Brigham and Women's Hospital, Boston
JFK Medical Center, Edison
Tom Baker Cancer Center, Calgary
CancerCare Manitoba, Winnipeg
Ottawa Hospital, Ottawa
Sunnybrook Research Institute, Toronto
Princess Margaret Cancer Center, Toronto
Montreal Neurological Institute and Hospital, Montreal
Istituto Oncologico Veneto, Padua
Sint Elisabeth Ziekenhuis, Tilburg
Vrije Universiteit Medisch Centrum (VUMC), Amsterdam
Erasmus Medisch Centrum Daniel den Hoed, Rotterdam
Universitair Medisch Centrum Utrecht, Utrecht
University Hospitals Birmingham NHS Foundation Trust, Birmingham
Edinburgh Cancer Centre - Western General Hospital, Edinburgh
Guy's Hospital, London
The Royal Marsden NHS Foundation Trust, London
The Christie NHS Foundation Trust, Manchester
Lead Sponsor
Orbus Therapeutics, Inc.
INDUSTRY